BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Sunday, May 12, 2024
Home
»
Newsletters
» BioWorld Science
BioWorld Science
Sep. 19, 2001
View Archived Issues
Synthetic peptide-based treatment for MS completes phase II trial in Canada
Read More
Tracleer NDA approvable, says FDA
Read More
Pivotal trial to begin soon for inhalable therapy for hereditary emphysema
Read More
Collagenase product for Dupuytren's disease heads for pivotal trials
Read More
Orion drops development of gel formulation of progestin
Read More
XTL continues to build strong infectious disease therapeutic pipeline
Read More
M-40403 improves diabetic vascular dysfunction and nerve damage
Read More
Levodopa with physiotherapy may improve motor recovery in stroke
Read More
Novel class of small nonpeptidyl compounds selectively inhibit malarial plasmepsins
Read More
Elastase inhibitors such as elafin may have clinical utility in intimal hyperplasia
Read More
Abbott presents new research findings in the area of protein farnesyltransferase inhibitors
Read More
New chemical series from American Cyanamid inhibits TACE and MMPs
Read More
Inhibitors of uPA binding and use as antitumor agents discussed by Roche
Read More
Pfizer scientists identify a series of CCR1 antagonists
Read More
Use of metabotropic glutamate receptor potentiators discussed by Lilly
Read More
Ortho-McNeil reports substituted amino acids that inhibit neutral sphingomyelinase activity
Read More
Animal studies support development of pyridoxamine for diabetic complications
Read More
Bradykinin B2 receptor modulators described in patent by Neurogen group
Read More
Tumor-imaging agents with selective affinity for vitronectin receptors
Read More
Inhibitex enters into partnership with Wyeth Lederle Vaccines
Read More
Negative results obtained in phase II GPG study
Read More
Broad development program under way for siplizumab
Read More
Enrollment of patients completed for phase III INS-365 Ophthalmic clinical program
Read More
FDA grants priority review status to etanercept for treatment of psoriatic arthritis
Read More
Optimization of anti-IL-9 antibody initiated
Read More